Equities analysts predict that Nevro Corp (NYSE:NVRO) will announce $88.57 million in sales for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Nevro’s earnings, with estimates ranging from $87.00 million to $91.20 million. Nevro posted sales of $68.44 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 29.4%. The firm is expected to report its next quarterly earnings report on Monday, May 14th.
On average, analysts expect that Nevro will report full year sales of $88.57 million for the current financial year, with estimates ranging from $403.00 million to $407.60 million. For the next year, analysts expect that the business will report sales of $480.83 million per share, with estimates ranging from $459.23 million to $502.50 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Nevro.
Nevro (NYSE:NVRO) last issued its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The firm had revenue of $97.96 million for the quarter, compared to the consensus estimate of $96.87 million. Nevro had a negative return on equity of 15.01% and a negative net margin of 11.22%. The company’s revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.34) EPS.
NVRO has been the topic of a number of research reports. BidaskClub lowered Nevro from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. BMO Capital Markets reiterated a “buy” rating and issued a $100.00 price target on shares of Nevro in a research report on Thursday, December 14th. ValuEngine lowered Nevro from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Canaccord Genuity reduced their price target on Nevro from $120.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, November 7th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $110.00 price target (up previously from $105.00) on shares of Nevro in a research report on Tuesday, November 7th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $99.25.
Shares of Nevro (NYSE NVRO) traded up $2.08 during mid-day trading on Friday, reaching $82.73. The company had a trading volume of 365,923 shares, compared to its average volume of 390,507. The company has a market cap of $2,390.54, a price-to-earnings ratio of -64.64 and a beta of -0.51. Nevro has a twelve month low of $65.00 and a twelve month high of $97.70. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.61 and a quick ratio of 5.91.
In other news, Director Wilfred E. Jaeger sold 10,000 shares of the business’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $80.48, for a total value of $804,800.00. Following the transaction, the director now directly owns 1,518 shares of the company’s stock, valued at approximately $122,168.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew H. Galligan sold 7,000 shares of the business’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $80.10, for a total value of $560,700.00. The disclosure for this sale can be found here. Insiders sold a total of 31,458 shares of company stock worth $2,569,562 in the last quarter. Corporate insiders own 9.10% of the company’s stock.
Several large investors have recently made changes to their positions in NVRO. State Street Corp lifted its stake in shares of Nevro by 16.7% in the 2nd quarter. State Street Corp now owns 538,517 shares of the medical equipment provider’s stock valued at $40,082,000 after purchasing an additional 77,208 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Nevro by 15.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,409 shares of the medical equipment provider’s stock valued at $1,593,000 after purchasing an additional 2,795 shares during the period. California State Teachers Retirement System lifted its stake in shares of Nevro by 3.6% in the 2nd quarter. California State Teachers Retirement System now owns 49,063 shares of the medical equipment provider’s stock valued at $3,652,000 after purchasing an additional 1,689 shares during the period. Strs Ohio lifted its stake in shares of Nevro by 1,982.3% in the 3rd quarter. Strs Ohio now owns 8,329 shares of the medical equipment provider’s stock valued at $756,000 after purchasing an additional 7,929 shares during the period. Finally, Pictet Asset Management Ltd. lifted its stake in shares of Nevro by 41.0% in the 3rd quarter. Pictet Asset Management Ltd. now owns 201,992 shares of the medical equipment provider’s stock valued at $18,357,000 after purchasing an additional 58,738 shares during the period.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2018/03/14/88-57-million-in-sales-expected-for-nevro-corp-nvro-this-quarter.html.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.